Phase 4 N=136 Randomized Single-blind Treatment

Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

Urinary Tract Diseases

Bottom Line

View on ClinicalTrials.gov: NCT02805504 ↗

Enrolled (actual)

136

Serious AEs

8.8%

Results posted

Apr 2024

Primary outcome: Primary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Exparel (Drug); Marcaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Loma Linda University
Primary completion: May 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Total Opioid Consumption	16.4; 15.3	—
PRIMARY Postoperative Pain Assessment	4.6; 4.6	—
PRIMARY Length of Hospital Stay	37; 36	—
PRIMARY Postoperative Complications	6; 6	—

Summary

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

Eligibility Criteria

Inclusion Criteria

Patients undergoing urologic surgery.

Exclusion Criteria

Pregnant and/or nursing mothers.
Allergy to bupivacaine.
History of drug/alcohol abuse.
Severe cardiovascular, hepatic, renal disease or neurological impairment.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02805504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.